SEC Form 4 · accession 0000899243-18-025713
ALPINE IMMUNE SCIENCES, INC. · ALPN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stanford L Peng
Officer — See Remarks
Period of report
Sep 28, 2018
Accepted (ET)
Oct 2, 2018 · 6:05 am EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001626199
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to buy)F1,F2 | $6.33 | Sep 28, 2018 | A | 250,000 | A | — | Sep 27, 2028 | Common Stock | 250,000 | 250,000 | D |
Explanation of responses
- F1The exercise price is equal to the closing price per share of Common Stock as reported on the Nasdaq Global Market on the date of grant.
- F21/2 of the shares subject to the option become vested and exercisable on October 1, 2020 and the balance of the shares subject to the option become vested and exercisable on October 1, 2022, subject to continued service through each such date.
Remarks
Exec VP of Research and Development and CMO